- Tytuł:
-
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/
r ) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. - Autorzy:
- Corporate Authors:
- A5288 Study team
- Źródło:
- Journal of the International AIDS Society [J Int AIDS Soc] 2022 Jun; Vol. 25 (6), pp. e25905.
- Typ publikacji:
- Journal Article; Research Support, N.I.H., Extramural
- MeSH Terms:
-
Anti-HIV Agents*/therapeutic use
HIV Infections */drug therapy
HIV Protease Inhibitors*/therapeutic use
HIV-1*/genetics
Anti-Retroviral Agents/therapeutic use ; Darunavir/therapeutic use ; Female ; Humans ; Male ; Nitriles ; Pyrimidines ; RNA/therapeutic use ; Raltegravir Potassium/adverse effects ; Ritonavir/therapeutic use ; Viral Load
Czasopismo naukowe